Search

Your search keyword '"Cobo S"' showing total 237 results

Search Constraints

Start Over You searched for: Author "Cobo S" Remove constraint Author: "Cobo S"
237 results on '"Cobo S"'

Search Results

1. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

2. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer

3. Variación patogénica y fuentes de resistencia a Colletotrichum lindemuthianum Sacc & magn Scrib., patógeno de la antracnosis del frijol, en Colombia Variación patogénica y fuentes de resistencia a Colletotrichum lindemuthianum (Sacc & Magn) Scrib., patógeno de la antracnosis del fríjol, en Colombia

4. P2.16-02 Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial

6. 237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy

7. Reporte de casos:: leucemia/linfoma de células T del adulto asociada al virus HTLV-1

8. 234P Real-world treatment patterns and outcomes of patients receiving palbociclib plus endocrine therapy in Spain: Subgroup analysis based on age, sites and number of metastatic locations, menopausal status and dose received from PALBOSPAIN study

9. 114P Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

10. 218P Characteristics and outcomes of HER2-low (H-Low) and HER2-zero (H-0) advanced breast cancer (ABC) patients (pts) from GEICAM/2014-03 (RegistEM) registry

11. 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies

13. 216P Relationship between regulatory T lymphocytes (Treg): Related genes and pathological response to neoadjuvant docetaxel-carboplatin in early-stage triple-negative breast cancer (TNBC)

15. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel

17. 281P Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays

18. 261P Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact

19. 258P Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)

20. Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses

21. 85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study

22. 62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials

23. Outcomes of high-risk breast cancer (BC) patients from El Alamo IV registry and GEICAM adjuvant clinical trials

24. 233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital

25. 406P Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC

26. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study

27. SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

28. TDS study of deuterium distribution in 3$^{rd}$ generation high strength steels as a function of charging conditions and cold rolling

29. Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients

30. SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

31. Hydrogen distribution in 3rd generation high strength steels and its effect on mechanical properties

32. Hydrogen distribution in a MnAl high strength steel and its effect on mechanical properties

33. Etude de la distribution de l'hydrogene incorpore a haute temperature dans un acier MnAl et son effet sur les proprietes mecaniques

35. The chemokine IP10 (CXCL10) dominates the long-term immune response stimulated by BCG treatment of non-muscle invasive bladder cancer, but a high concentration of IP10 in urine is strongly indicative of risk for the development of intolerance to BCG

37. Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients

38. Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms

39. Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial

41. Deformation substructure of austenite evaluated by crystallographic reconstruction and its influence on microstructure inheritance in low carbon steels

43. 942 - The chemokine IP10 (CXCL10) dominates the long-term immune response stimulated by BCG treatment of non-muscle invasive bladder cancer, but a high concentration of IP10 in urine is strongly indicative of risk for the development of intolerance to BCG

44. Soporte nutricional y factores de riesgo de aparición de fístulas enterocutáneas

45. Soporte nutricional y factores de riesgo de aparición de fístulas enterocutáneas

50. 30 CD56 bright natural killer cells primed by innate immune cytokines dominate the immune response stimulated by BCG to non-muscle invasive bladder cancer

Catalog

Books, media, physical & digital resources